Your browser is no longer supported. Please, upgrade your browser.
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own3.50% Shs Outstand101.84M Perf Week19.24%
Market Cap5.99B Forward P/E- EPS next Y-0.56 Insider Trans-9.01% Shs Float99.57M Perf Month32.88%
Income-24.40M PEG- EPS next Q0.11 Inst Own68.00% Short Float9.05% Perf Quarter21.80%
Sales123.70M P/S48.43 EPS this Y205.90% Inst Trans0.37% Short Ratio6.03 Perf Half Y49.18%
Book/sh4.84 P/B12.17 EPS next Y-133.30% ROA-4.80% Target Price66.64 Perf Year59.70%
Cash/sh2.82 P/C20.87 EPS next 5Y7.33% ROE-5.60% 52W Range19.51 - 73.72 Perf YTD-7.17%
Dividend- P/FCF- EPS past 5Y20.60% ROI24.90% 52W High-20.13% Beta1.88
Dividend %- Quick Ratio7.40 Sales past 5Y295.20% Gross Margin- 52W Low201.79% ATR3.26
Employees134 Current Ratio7.40 Sales Q/Q-35.80% Oper. Margin-27.00% RSI (14)74.40 Volatility6.85% 5.78%
OptionableYes Debt/Eq0.00 EPS Q/Q-165.00% Profit Margin-19.70% Rel Volume0.90 Prev Close58.56
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume1.49M Price58.88
Recom2.00 SMA2023.31% SMA5034.70% SMA20047.90% Volume1,350,906 Change0.55%
May-13-20Initiated RBC Capital Mkts Outperform $62
May-08-20Upgrade Oppenheimer Perform → Outperform $58
Apr-15-20Upgrade Cantor Fitzgerald Neutral → Overweight $55 → $60
Mar-24-20Upgrade SVB Leerink Underperform → Mkt Perform $29
Mar-17-20Initiated Goldman Neutral $45
Jan-21-20Initiated SVB Leerink Underperform $32
Dec-13-19Initiated Oppenheimer Perform
Nov-29-19Reiterated Chardan Capital Markets Buy $45 → $81
Nov-27-19Reiterated B. Riley FBR Buy $59 → $83
Nov-25-19Upgrade Robert W. Baird Neutral → Outperform $70
Oct-24-19Downgrade Robert W. Baird Outperform → Neutral $39
Oct-22-19Reiterated Chardan Capital Markets Buy $32 → $45
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Oct-15-20 05:00PM  
04:12PM  
10:24AM  
Oct-14-20 05:29PM  
Oct-10-20 08:04AM  
Oct-08-20 09:20AM  
07:30AM  
Oct-06-20 10:46AM  
Sep-30-20 04:01PM  
Sep-24-20 04:30PM  
Sep-21-20 05:41AM  
Sep-17-20 11:28PM  
Sep-16-20 04:24PM  
11:48AM  
11:20AM  
10:22AM  
07:30AM  
Sep-10-20 10:37AM  
Sep-08-20 07:30AM  
07:30AM  
Sep-07-20 07:01AM  
Aug-31-20 04:50AM  
Aug-28-20 07:30AM  
Aug-18-20 08:00AM  
07:30AM  
Aug-11-20 07:30AM  
Aug-10-20 07:15AM  
Aug-05-20 04:00PM  
Jul-29-20 07:30AM  
Jul-28-20 07:08PM  
11:59AM  
Jul-24-20 04:10PM  
Jul-18-20 07:17PM  
Jul-09-20 08:19AM  
07:30AM  
Jul-08-20 04:00PM  
10:13AM  
Jun-16-20 09:46PM  
09:30AM  
Jun-02-20 12:35PM  
May-30-20 06:35PM  
May-28-20 07:30AM  
May-24-20 10:10AM  
May-22-20 11:34AM  
May-19-20 07:02AM  
May-10-20 08:20AM  
May-08-20 09:30PM  
May-07-20 04:00PM  
May-01-20 04:00PM  
04:00PM  
Apr-30-20 07:52AM  
Apr-22-20 07:30AM  
Apr-20-20 06:31AM  
Apr-10-20 07:30AM  
Apr-06-20 06:26PM  
10:30AM  
Mar-20-20 02:15PM  
Mar-18-20 08:00PM  
Mar-17-20 04:10PM  
04:10PM  
Mar-15-20 08:30AM  
Mar-10-20 04:16PM  
Mar-03-20 07:30AM  
Mar-02-20 04:00PM  
Feb-13-20 04:47PM  
Feb-12-20 09:37PM  
Feb-07-20 09:36AM  
Feb-06-20 07:47AM  
Feb-05-20 04:00PM  
04:00PM  
07:43AM  
Feb-03-20 01:06PM  
Jan-24-20 05:31AM  
Jan-22-20 04:29PM  
07:30AM  
Jan-21-20 04:30PM  
Jan-16-20 03:55PM  
Jan-11-20 08:00AM  
Jan-10-20 11:51AM  
Jan-06-20 07:30AM  
Jan-02-20 08:00AM  
Dec-27-19 06:06PM  
Dec-26-19 05:27AM  
Dec-24-19 10:00AM  
Dec-23-19 10:21AM  
08:00AM  
Dec-20-19 07:30AM  
Dec-16-19 10:55PM  
04:15PM  
07:30AM  
Dec-13-19 06:12PM  
07:30AM  
Dec-11-19 03:46PM  
07:30AM  
Dec-06-19 04:01PM  
Dec-04-19 06:00AM  
Dec-03-19 09:26AM  
06:55AM  
Dec-02-19 04:48PM  
04:05PM  
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anzalone Christopher RichardChief Executive OfficerOct 23Sale58.21100,0005,821,0322,505,237Oct 23 07:35 PM
Myszkowski Kenneth AllenChief Financial OfficerOct 20Option Exercise6.1529,166179,371456,834Oct 22 06:02 PM
Myszkowski Kenneth AllenChief Financial OfficerOct 20Sale54.0429,1661,576,131427,668Oct 22 06:02 PM
Ferrari MauroDirectorOct 09Sale48.0010,000480,00030,971Oct 13 06:01 PM
Anzalone Christopher RichardChief Executive OfficerAug 13Option Exercise9.9050,000495,0002,655,237Aug 14 06:08 PM
Anzalone Christopher RichardChief Executive OfficerAug 13Sale41.3550,0002,067,5002,605,237Aug 14 06:08 PM
Anzalone Christopher RichardChief Executive OfficerJun 25Sale38.81100,0003,881,0172,605,237Jun 26 06:02 PM
De Backer MarianneDirectorJun 15Buy31.3350015,66516,500Jun 24 06:10 PM
PERRY MICHAEL SDirectorMay 14Option Exercise3.7077,000285,20085,000May 18 06:27 PM
PERRY MICHAEL SDirectorMay 12Sale35.8336,0001,289,8918,000May 13 06:48 PM
Waddill William D.DirectorMay 11Sale36.5426,000950,04028,000May 13 06:45 PM
GIVEN BRUCE DChief Operating OfficerApr 28Option Exercise8.614,19736,131855,831Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 28Sale40.005,101204,040850,730Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 27Option Exercise5.192001,038851,934Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 27Sale40.0030012,000851,634Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 20Option Exercise8.1416,256132,286875,249Apr 22 07:00 PM
GIVEN BRUCE DChief Operating OfficerApr 20Sale40.0023,515940,600851,734Apr 22 07:00 PM
De Backer MarianneDirectorApr 15Buy35.4050017,70016,000Jun 24 06:10 PM
GIVEN DOUGLAS BDirectorApr 14Sale36.8925,000922,250155,925Apr 16 07:47 PM
De Backer MarianneDirectorMar 16Buy23.9450011,97015,500Jun 24 06:10 PM
De Backer MarianneDirectorMar 12Buy24.8050012,40015,000Jun 24 06:10 PM
De Backer MarianneDirectorMar 11Buy28.6050014,30014,500Jun 24 06:10 PM
De Backer MarianneDirectorFeb 28Buy34.3950017,19514,000Jun 24 06:10 PM
De Backer MarianneDirectorFeb 27Buy35.0750017,53513,500Jun 24 06:10 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 25Option Exercise8.8443,445384,145427,668Feb 27 05:41 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Option Exercise5.1933,351173,092424,536Jan 23 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Sale49.4440,3131,992,925384,223Jan 23 06:15 PM
De Backer MarianneDirectorJan 13Buy54.9550027,47513,000Jun 24 06:10 PM
GIVEN BRUCE DChief Operating OfficerJan 06Sale60.1335,6132,141,285858,993Jan 08 06:35 PM
O'Brien PatrickGeneral CounselJan 06Sale60.1214,625879,261258,375Jan 08 06:33 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 06Sale60.1120,0001,202,201391,185Jan 08 06:31 PM
Anzalone Christopher RichardChief Executive OfficerDec 24Sale63.5083,3335,291,6461,805,237Dec 27 04:54 PM
Anzalone Christopher RichardChief Executive OfficerDec 13Sale66.7383,3335,560,4891,888,570Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale67.50100,0006,749,6301,971,903Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 03Sale61.5812,033740,9522,071,903Dec 04 06:48 PM
Anzalone Christopher RichardChief Executive OfficerDec 02Sale69.1537,9672,625,5702,083,936Dec 04 06:48 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 05Option Exercise5.1912,64965,648326,185Nov 07 06:45 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Option Exercise7.7537,884293,601351,420Nov 01 07:32 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Sale40.8537,8841,547,378313,536Nov 01 07:32 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.